Innovation Pharmaceuticals Inc. (OTC:IPIX) Q3 2017 Earnings Conference Call June 8, 2017 11:00 AM ET
Executives
Leo Ehrlich - CEO
Arthur Bertolino - President & Chief Medical Officer
Analysts
Sarah Rubin - IMPAQ International
Operator
Good day ladies and gentlemen, and welcome to the Innovation Pharmaceuticals' Shareholder and Investor Conference Call. All lines have been placed on a listen-only mode. [Operator instructions]
At this time, it is my pleasure to turn the floor over to your host, CEO, Leo Ehrlich. Sir, the floor is yours.
Leo Ehrlich
Okay. Thank you, Angelica. I am Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. Good morning, everyone and thank you for attending this live shareholder conference call.
Before we begin, I would like to remind listeners that this call will contain forward-looking statements made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, and any other statements which are not historical facts. These statements involve risks, uncertainties, and assumptions that could cause Innovation Pharmaceuticals' actual results and experience to different materially from anticipated results and expectations expressed in these forward-looking statements.
Innovation Pharmaceuticals has in some cases identified forward-looking statements by using words such as anticipates, believes, hopes, expects, plans, intends, goal, potential, may and similar expressions among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, are Innovation Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Innovation Pharmaceutical compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere.
- Read more current IPIX analysis and news
- View all earnings call transcripts